EA200401252A1 - Микрочастицы лекарственных веществ - Google Patents

Микрочастицы лекарственных веществ

Info

Publication number
EA200401252A1
EA200401252A1 EA200401252A EA200401252A EA200401252A1 EA 200401252 A1 EA200401252 A1 EA 200401252A1 EA 200401252 A EA200401252 A EA 200401252A EA 200401252 A EA200401252 A EA 200401252A EA 200401252 A1 EA200401252 A1 EA 200401252A1
Authority
EA
Eurasian Patent Office
Prior art keywords
microparticles
medicinal substances
making
methods
same
Prior art date
Application number
EA200401252A
Other languages
English (en)
Inventor
Ицхак Е. Лернер
Веред Розенбергер
Моше Флашнер-Барак
Анна Драбкин
Наоми Молдавски
Original Assignee
Тева Фармасьютикал Индастриес Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриес Лтд. filed Critical Тева Фармасьютикал Индастриес Лтд.
Publication of EA200401252A1 publication Critical patent/EA200401252A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/12—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution
    • B01J13/125—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution by evaporation of the solvent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предложены микрочастицы активных фармацевтических ингредиентов (лекарственных веществ), средства введения лекарственных веществ в организм пациента, содержащие такие микрочастицы, и способы их получения.Отчет о международном поиске был опубликован 2004.02.05.
EA200401252A 2002-03-26 2003-03-25 Микрочастицы лекарственных веществ EA200401252A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36795702P 2002-03-26 2002-03-26
PCT/US2003/009327 WO2003082247A2 (en) 2002-03-26 2003-03-25 Drug microparticles

Publications (1)

Publication Number Publication Date
EA200401252A1 true EA200401252A1 (ru) 2005-04-28

Family

ID=28675427

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401252A EA200401252A1 (ru) 2002-03-26 2003-03-25 Микрочастицы лекарственных веществ

Country Status (17)

Country Link
US (6) US20030224059A1 (ru)
EP (5) EP2085074A1 (ru)
JP (1) JP2005531521A (ru)
KR (1) KR20040098023A (ru)
AT (1) ATE450252T1 (ru)
AU (2) AU2003226021B2 (ru)
CA (1) CA2480377A1 (ru)
DE (1) DE60330322D1 (ru)
DK (1) DK1487416T3 (ru)
EA (1) EA200401252A1 (ru)
ES (1) ES2334991T3 (ru)
HK (1) HK1069126A1 (ru)
IL (1) IL164152A0 (ru)
MX (1) MXPA04009385A (ru)
NZ (1) NZ535854A (ru)
PT (1) PT1487416E (ru)
WO (1) WO2003082247A2 (ru)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003226021B2 (en) 2002-03-26 2008-07-17 Teva Pharmaceutical Industries Ltd. Drug microparticles
WO2004028506A1 (en) * 2002-09-24 2004-04-08 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of fenofibrate having high bioavailability
MXPA05008902A (es) * 2003-02-20 2005-10-05 Teva Pharma Soluciones de drogas en mentol.
AU2004289252C1 (en) 2003-11-08 2013-06-20 Prothera Biologics, Inc. Preparation and composition of Inter-alpha inhibitor proteins from human plasma for therapeutic use
EP1691795A2 (en) * 2003-12-03 2006-08-23 LifeCycle Pharma A/S Pharmaceutical compositions comprising danazol
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
WO2006020984A2 (en) * 2004-08-13 2006-02-23 Teva Pharmaceutical Industries Ltd. Cyclosporin formulations
US20070148233A1 (en) * 2005-12-28 2007-06-28 Lerner E I Pharmaceutical formulations of fenofibrate having improved bioavailability
EP1861084A1 (en) * 2005-03-30 2007-12-05 Teva Pharmaceutical Industries Ltd. Improved formulations of fenofibrate containing menthol or peg/poloxamer
BRPI0609497A2 (pt) * 2005-03-30 2010-04-13 Teva Pharma formulações aprimoradas de fenofibrato
EP1707197A1 (en) 2005-03-30 2006-10-04 Teva Pharmaceutical Industries Ltd. Formulations containing fenofibrate and a surfactant mixture
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
US20070015833A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing menthol
EP3263117A1 (en) 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
AU2006330526B2 (en) * 2005-12-22 2012-09-27 Oakwood Laboratories, Llc Sublimable sustained release delivery system and method of making same
JP2009522258A (ja) * 2005-12-28 2009-06-11 テバ ファーマシューティカル インダストリーズ リミティド 増大したバイオアベイラビリティを有するフェノフィブラートの医薬製剤
ATE429902T1 (de) 2005-12-28 2009-05-15 Teva Pharma Pharmazeutische formulierungen mit fenofibrat mit verbesserter bioverfügbarkeit
RU2008142388A (ru) * 2006-04-03 2010-05-10 Тева Фармасьютикл Индастриес Лтд. (Il) Микрочастицы лекарственного вещества
WO2008110534A1 (en) * 2007-03-13 2008-09-18 Sandoz Ag Pharmaceutical compositions of poorly soluble drugs
KR100790954B1 (ko) * 2007-09-13 2008-01-04 영남대학교 산학협력단 이트라코나졸 함유 젤라틴 초미세 미립구
PT2291654T (pt) 2008-05-28 2018-06-15 Prothera Biologics Inc Preparação e composição de proteínas inibidoras de interalfa do sangue
CN102307576A (zh) * 2008-12-15 2012-01-04 班纳制药公司 用于增强水不溶性活性剂的释放和吸收的方法
WO2010085780A1 (en) * 2009-01-26 2010-07-29 Teva Pharmaceutical Industries Ltd. Processes for coating a carrier with microparticles
NZ596610A (en) 2009-05-27 2014-04-30 Samyang Biopharmaceuticals A poorly soluble drug containing microsphere with improved bioavailability and method of preparing the same
US9522963B2 (en) 2011-06-29 2016-12-20 Covidien Lp Dissolution of oxidized cellulose
JP6285866B2 (ja) 2011-11-23 2018-02-28 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然複合ホルモン補充製剤および療法
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150140097A1 (en) * 2012-04-25 2015-05-21 Spi Pharma, Inc. Crystalline microspheres and the process for manufacturing the same
US9271937B2 (en) 2012-05-31 2016-03-01 Covidien Lp Oxidized cellulose microspheres
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9499636B2 (en) 2012-06-28 2016-11-22 Covidien Lp Dissolution of oxidized cellulose and particle preparation by cross-linking with multivalent cations
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10413566B2 (en) 2013-03-15 2019-09-17 Covidien Lp Thixotropic oxidized cellulose solutions and medical applications thereof
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
FR3039990B1 (fr) 2015-08-10 2018-07-06 Rhodia Operations Procede d'encapsulation
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017205835A1 (en) 2016-05-26 2017-11-30 Allergan, Inc. Production of rounded salt particles
WO2018045103A1 (en) * 2016-08-30 2018-03-08 Allergan, Inc. Method of manufacturing coated beads
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
JP2024505429A (ja) 2021-01-15 2024-02-06 アクエスティブ セラピューティクス インコーポレイテッド プロドラッグ組成物及び治療の方法
WO2023015183A1 (en) * 2021-08-02 2023-02-09 Cornell University Polymer nanoparticles via condensed droplet polymerization

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089818A (en) 1960-06-02 1963-05-14 Baxter Laboratories Inc Water dispersible antibiotics
DE2246013A1 (de) * 1972-09-20 1974-03-28 Boehringer Mannheim Gmbh Verfahren zur herstellung von poroesen tabletten
JPS5429566B2 (ru) 1974-09-13 1979-09-25
US4900775A (en) * 1988-02-29 1990-02-13 Gaf Chemicals Corporation Solubilization of complexes of water-insoluble organic compounds by aqueous solutions of polyvinylpyrrolidone
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
GB8921710D0 (en) * 1989-09-26 1989-11-08 Mentholatum Co Ltd Ibuprofen triturates and topical compositions containing same
HUT75616A (en) * 1992-03-17 1997-05-28 Pfizer Method for prooucing porous delivery devices
KR100333115B1 (ko) * 1992-11-17 2002-12-02 미츠비시 파마 코포레이션 항정신병약함유서방성마이크로스피어및이의제조방법
IT1264020B (it) * 1993-01-28 1996-09-09 Recordati Chem Pharm Procedimento per la preparazione di microgranuli idonei alla sospensione in liquidi
SI9300504A (en) * 1993-09-28 1995-04-30 Krka Process for preparation solid dispersions and deposits of calcium antagonist dihidropyrimidine derivates and pharmaceutical compositions comprising the same
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
IE75744B1 (en) * 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
EP0906104A4 (en) * 1996-03-25 2003-12-10 Lilly Co Eli PAIN TREATMENT PROCESS
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
US5985248A (en) * 1996-12-31 1999-11-16 Inhale Therapeutic Systems Processes for spray drying solutions of hydrophobic drugs and compositions thereof
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
KR19990001564A (ko) 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
US6027747A (en) 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6337092B1 (en) * 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
ES2334435T3 (es) * 2000-04-26 2010-03-10 Elan Pharma International Limited Aparato de molienda humeda higienica.
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US20020001617A1 (en) * 2000-05-26 2002-01-03 Chang-Hyun Lee Rapidly disintegrating tablet and process for the manufacture thereof
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
US20040043043A1 (en) 2000-09-20 2004-03-04 Schlyter Jimmy Hirschsprung Preparation of emulsions and concentrates thereof
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
JP2005504090A (ja) 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
AU2003226021B2 (en) 2002-03-26 2008-07-17 Teva Pharmaceutical Industries Ltd. Drug microparticles
US20020193386A1 (en) * 2002-03-28 2002-12-19 Inigo Pfeiffer Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
WO2004075874A1 (en) 2003-02-28 2004-09-10 Anbics Patents-Licences Ag Method for treatment and prevention of acute and chronic pseudomonas aeruginosa airway infections with inhalable macrolides
US20040185108A1 (en) * 2003-03-18 2004-09-23 Short Robert E. Method of preparing gas-filled polymer matrix microparticles useful for delivering drug
CA2541382A1 (en) 2003-10-10 2005-04-21 Lifecycle Pharma A/S A solid dosage form comprising a fibrate and a statin
RU2006121973A (ru) 2003-11-21 2007-12-27 Галдерма Ресерч Энд Девелопмент, С.Н.С. (Fr) Распыляемая композиция для введения производных витамина d

Also Published As

Publication number Publication date
US20060141050A1 (en) 2006-06-29
EP1487416A2 (en) 2004-12-22
EP2085074A1 (en) 2009-08-05
ES2334991T3 (es) 2010-03-18
US20060141052A1 (en) 2006-06-29
DK1487416T3 (da) 2010-03-29
JP2005531521A (ja) 2005-10-20
EP2087882A1 (en) 2009-08-12
CA2480377A1 (en) 2003-10-09
US8663703B2 (en) 2014-03-04
PT1487416E (pt) 2010-01-25
DE60330322D1 (de) 2010-01-14
US20100092568A1 (en) 2010-04-15
MXPA04009385A (es) 2005-01-25
AU2003226021A1 (en) 2003-10-13
EP1487416B1 (en) 2009-12-02
US20030224059A1 (en) 2003-12-04
KR20040098023A (ko) 2004-11-18
US20060141051A1 (en) 2006-06-29
US9107832B2 (en) 2015-08-18
US20140134256A1 (en) 2014-05-15
EP2085072A1 (en) 2009-08-05
WO2003082247A3 (en) 2004-02-05
HK1069126A1 (en) 2005-05-13
WO2003082247A2 (en) 2003-10-09
NZ535854A (en) 2006-08-31
EP2085073A1 (en) 2009-08-05
ATE450252T1 (de) 2009-12-15
AU2003226021B2 (en) 2008-07-17
AU2008230007A1 (en) 2008-11-13
IL164152A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
EA200401252A1 (ru) Микрочастицы лекарственных веществ
EA200501586A1 (ru) Фармацевтические продукты
BRPI0415858A (pt) compostos de medicamentos terapêuticos modificados por tocoferol
EE05506B1 (et) Ravimi manustamise vahend eriti progestiinide ja”strogeenide manustamiseks
WO2005041925A3 (en) Compositions and dosage forms for enhanced absorption
WO2004054542A3 (en) Oral drug delivery system comprising high viscosity liquid carrier materials
DE69823869D1 (de) Pharmazeutische hydrogelformulierungen, vorrichtungen zur arzneistoffabgabe und verfahren
DE602005010788D1 (de) Pharmazeutische Zusammensetzungen zur sicheren Verabreichung von bei der Behandlung von Drogenabhängigkeit verwendeten Arzneimitteln
BRPI0406911A (pt) Produto farmacêutico e/ou cosmético
MXPA05010565A (es) Sistemas de suminsitro de farmacos que comprenden un ingrediente activo encapsulado.
DZ3227A1 (fr) Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
WO2006037948A3 (en) Methods and kits for delivering drugs by nebulisation
SE0003449D0 (sv) Anticancer compositions
NO20055173L (no) Farmasoytisk kombinasjonsblanding omfattende modafinil og et annet legemiddel
EA200602137A1 (ru) Гидрогелевые препараты интерферона
ATE292453T1 (de) Antivirale arznei
FR2764889B1 (fr) Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
IS8430A (is) Lyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
AR034493A1 (es) Combinacion de principios activos para el tratamiento medico de toxicomanias.
EA200600603A1 (ru) Оральная система доставки лекарственного препарата
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
MA27418A1 (fr) Ensemble de distribution de medicament.
BR0306843A (pt) Formulações sedativas de não-benzodiazepina
EP1603595A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE